The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment

被引:4
|
作者
Dehghan, Razieh [1 ]
Bahreini, Fatemeh [1 ]
Najafi, Rezvan [1 ]
Saidijam, Massoud [1 ]
Amini, Razieh [1 ]
机构
[1] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; SIGNALING PATHWAY; 5-FLUOROURACIL; APOPTOSIS; SURVIVIN; CHEMOSENSITIZATION; CHEMORESISTANCE; SENSITIVITY; SUPPRESSION;
D O I
10.1155/2021/6635874
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives. Chemotherapy is considered to be essential in the treatment of patients with colorectal cancer (CRC), but drug resistance reduces its efficacy. Many patients with advanced CRC eventually show resistance to 5-fluorouracil (5-FU) therapy. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients' response. Zerumbone (ZER), which is derived from ginger, has been studied for its growth inhibitory function in various types of cancer. Methods. The cytotoxic effects of ZER and 5-FU alone and their combination, on the SW48 and HCT-116 cells, were examined, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The mRNA and protein levels of beta-catenin, survivin, and vimentin were measured in treated CRC cells, using qRT-PCR and western blot. Colony formation assay, scratch test, and flow cytometry were performed to detect the changes of proliferation, migration, and apoptosis. Key Findings. In HCT-116- and SW48-treated cells, the proliferation, the gene and protein expression levels of the markers, the migration, the colony formation, and the survival rates were all significantly reduced compared to the control groups, and the sharpest decline was observed in the 5-FU+ZER treatment groups. Conclusions. Combination therapy has shown promising results in CRC cells, especially in drug-resistant cells.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] COMBINATION CHEMOTHERAPY OF CISPLATIN AND 5-FU IN ADVANCED COLORECTAL-CARCINOMA
    DY, C
    GIL, A
    ALGARRA, SM
    APARICIO, LA
    CALVO, F
    HERRANZ, P
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 465 - 468
  • [32] Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection
    Jettte, Lucie
    Bissoon-Haqqani, Seema
    Le Francois, Brice
    Maroun, Jean A.
    Birnboim, H. Chaim
    ANTICANCER RESEARCH, 2008, 28 (4B) : 2175 - 2180
  • [33] Severe toxicity of a standard 5-FU/Leucovorin combination in patients with colorectal cancer: A prospective study
    Tsalic, M
    Bar-Sela, G
    Menashe, N
    Vizel, B
    Haim, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S77 - S77
  • [34] To 5-FU or not to 5-FU? When, how and why to use the new active agents in advanced colorectal cancer
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1296 - 1296
  • [35] Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
    Gamelin, EC
    DanquechinDorval, EM
    Dumesnil, YF
    Maillart, PJ
    Goudier, MJ
    Burtin, PC
    Delva, RG
    Lortholary, AH
    Gesta, PH
    Larra, FG
    CANCER, 1996, 77 (03) : 441 - 451
  • [36] Phenylacetaldehyde induces apoptosis through endoplasmic reticulum and potentiates the effect of 5-FU treatment in colorectal cancer cells
    Ferrandon, Sylvain
    Kong, Cheng
    Fedro, Joseph
    Aoun, Rami-James
    Chitchumroonchokchai, Chureeporn
    Clinton, Steven
    Kalady, Matthew F.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Knockout of SIRT4 decreases chemosensitivity to 5-FU in colorectal cancer cells
    Zhu, Yuanyuan
    Wang, Guangyu
    Li, Xiaobo
    Wang, Tianzhen
    Weng, Mingjiao
    Zhang, Yanqiao
    ONCOLOGY LETTERS, 2018, 16 (02) : 1675 - 1681
  • [39] Metabolomic analysis on pharmacological responses to oxaliplatin plus 5-FU in colorectal cancer cells
    Nishimuta, Akito
    Tsuzaki, Junya
    Ikoma, Yusuke
    Otani, Yuki
    Irie, Hidehiro
    Suzuki, Tetsuya
    Sugimoto, Masahiro
    Soga, Tomoyoshi
    Tanigawara, Yusuke
    CANCER RESEARCH, 2012, 72
  • [40] Building on the foundation of 5-FU to treat metastatic colorectal cancer
    Eng, Cathy
    ONCOLOGY-NEW YORK, 2008, 22 (04): : 462 - +